Drugs / vadastuximab talirine
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02326584 | Dec 2014 → Jan 2017 | acute myeloid leukemia | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01902329 | Jul 2013 → Mar 2016 | acute promyelocytic leukemia | Seagen Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02706899 | Feb 2016 → Nov 2017 | myelodysplastic syndrome | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02614560 | Nov 2015 → Feb 2017 | acute myeloid leukemia | Seagen Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02785900 | May 2016 → Oct 2017 | acute myeloid leukemia | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vadastuximab talirine | “Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33” PMID 29196412 ↗ Dec 2017 |
| Known as | 33A | “Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33” PMID 29196412 ↗ Dec 2017 |
| Known as | SGN-CD33A | “SGN-CD33A (vadastuximab talirine)” NCT02614560 ↗ |
| Known as | Vadastuximab talirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990021 ↗ |
| Known as | vadastuximab talirine, SGN-CD33A | “vadastuximab talirine, SGN-CD33A” NCT02785900 ↗ |
| Route | Intravenous | “Patients received vadastuximab talirine IV on day 1 (5-60 µg/kg) or on days 1 and 4 (20 µg/kg) of 21-day cycles” PMID 29196412 ↗ Dec 2017 |
| Target | CD33 | “Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33” PMID 29196412 ↗ Dec 2017 |